BIOHAVEN LTD (BHVN)
Health Care · Biopharmaceutical development (immunology and neuroscience focus) · NYSE
Biohaven is a clinical-stage biopharmaceutical company pioneering extracellular protein degraders and targeted ion channel modulators for autoimmune, neurological, and metabolic diseases.
What BIOHAVEN LTD does
Biohaven Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing treatments in immunology, neuroscience, and oncology. The company is advancing a portfolio of therapeutics built on proprietary drug development platforms, including Kv7 ion channel modulation for epilepsy, extracellular protein degraders (MoDE and TRAP) for immunological diseases, and myostatin-activin pathway targeting agents for neuromuscular and metabolic diseases including obesity.
Themes: ["Extracellular protein degradation","Autoimmune disease (Graves' disease, IgA nephropathy)","Neuroscience / ion channel modulation","Obesity and metabolic disease","Epilepsy","Oncology","Immunology"]
Fundamentals
- Price$16.79 as of 2026-07-09 close
- Market cap$2.5B as of 2026-07-10
- 1-year return+16.0% as of 2026-07-09 close
- ROE-450.0% as of 2026-07-10
- Debt / equity1.87 as of 2026-07-10
- Beta2.98 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Regeneron Pharmaceuticals (REGN)
- AstraZeneca (AZN)
- GSK / GlaxoSmithKline (GSK)
- Amgen (AMGN)
- Caltech / Caltech-affiliated biotech
- Alnylam Pharmaceuticals (ALNY)
- Vertex Pharmaceuticals (VERX)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.